Evidence map›Paper›PMID 30510462›Full record

ReviewJournal of blood medicine2018

Phenotypical variability in congenital FVII deficiency follows the ISTH-SSC severity classification guidelines: a review with illustrative examples from the clinic.

Shilpa Jain, Jennifer Donkin, Mary-Jane Frey, Skye Peltier, Sriya Gunawardena, David L Cooper

Open access · goldAbstract readReview
In one paragraph

Review in Journal of blood medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. [Congenital factor Ⅶ deficiency: a retrospective analysis of 43 cases].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2020
    Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Shilpa JainHemophilia Center of Western New York, Buffalo, NY, USA, sjain@upa.chob.edu.
Jennifer DonkinHemostasis and Thrombosis Center, Children's Hospital Los Angeles, Los Angeles, CA, USA.
Mary-Jane FreyChildren's Hospital of Michigan, Detroit, MI, USA.
Skye PeltierCenter for Bleeding and Clotting Disorders, University of Minnesota, Minneapolis, MN, USA.
Sriya GunawardenaClinical Development, Medical and Regulatory Affairs, Novo Nordisk Inc., Plainsboro, NJ, USA.
David L CooperClinical Development, Medical and Regulatory Affairs, Novo Nordisk Inc., Plainsboro, NJ, USA.
Novo Nordisk (United States) · USChildren's Hospital of Los Angeles · USChildren's Hospital of Michigan · USUniversity of Minnesota · USWomen & Children's Hospital of Buffalo · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOne of the most common rare inherited bleeding disorders, congenital factor VII (FVII) deficiency typically has a milder bleeding phenotype than other rare bleeding disorders. Categorizing severity in terms of factor activity associated with hemophilia (severe <1%, moderate 1%-5%, mild 6%-40%) has led to the observation that bleeding phenotype does not follow closely with FVII activity. Over the past decade, large-scale global registries have investigated bleeding phenotype more thoroughly. The International Society on Thrombosis and Haemostasis has reclassified FVII deficiency as follows: severe, FVII <10%, risk of spontaneous major bleeding; moderate, FVII 10%-20%, risk of mild spontaneous or triggered bleeding; mild, FVII 20%-50%, mostly asymptomatic disease. CASE REPORTS: Eleven illustrative cases of congenital FVII deficiency adapted from clinical practice are described to demonstrate the variability in presentation and in relation to FVII activity levels. Severe FVII deficiency usually presents at a young age and carries the risk of intracranial hemorrhage, hemarthrosis, and other major bleeds. Moderate FVII deficiency tends to present later, often in adolescence and particularly in girls as they reach menarche. Milder disease may not be apparent until found incidentally on preoperative testing, during pregnancy/childbirth, or following unexplained bleeding when faced with hemostatic challenges.

conclusionIt is important for health care professionals to be aware of the new definitions of severity and typical presentations of congenital FVII deficiency. Failure to appreciate the risks of major bleeding, including intracerebral hemorrhage in those with FVII activity <10%, may put particularly young children at risk.

Indexed as

blood coagulation disorders/classificationblood coagulation factors/physiologyhumans’ rare diseases/classificationSeverity of Illness Index

Identifiers

PMID30510462
PMCPMC6250109
OpenAlexW2901076961

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.